Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma: a case report
2024

Intrathecal Pemetrexed for Leptomeningeal Metastases in Lung Cancer

Sample size: 1 publication Evidence: low

Author Information

Author(s): Emelie Gezelius, Maria Planck, Bassam Hazem, Seema Nagpal, Heather Wakelee

Primary Institution: Lund University

Hypothesis

Can intrathecal pemetrexed provide clinical benefit for patients with leptomeningeal metastases from lung adenocarcinoma?

Conclusion

Intrathecal pemetrexed may offer symptomatic relief and clinical improvement in patients with progressive leptomeningeal metastases due to lung adenocarcinoma.

Supporting Evidence

  • Intrathecal pemetrexed rapidly improved the patient's neurological symptoms.
  • The patient regained visual acuity and was able to walk short distances after treatment.
  • Treatment was well tolerated with minimal side effects.

Takeaway

This study shows that a special medicine called intrathecal pemetrexed can help people with a type of brain cancer caused by lung cancer feel better.

Methodology

The patient received intrathecal pemetrexed and was monitored for clinical improvement and side effects.

Limitations

The study is based on a single case report, limiting generalizability.

Participant Demographics

A 47-year-old woman with a 10-year history of metastatic ALK-positive NSCLC.

Digital Object Identifier (DOI)

10.1007/s00280-024-04735-8

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication